BioNTech acquires Eufets

Published: 5-Jun-2009
Media Ingredients Pharmaceutical

German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.


German biotech company BioNTech has acquired Eufets from Fresenius Biotech. Eufets is a GMP and GLP services specialist and under its new owner will retain all facilities, staff and contracts of the former company.

"The investment in Eufets is an excellent fit, endowing BioNTech with synergistic platforms and complementary expertise," said Dr Ugur Sahin, ceo of BioNTech.

The company said it would progress Eufets into a centre of excellence by developing and providing high-quality GMP/GLP services for recombinant vaccines, cell based therapies, gene- and immunotherapies.

Helmut Jeggle, chair of the supervisory board of BioNTech added: "The acquisition of Eufets is a logical step for our long-term strategy to build an excellent and competitive company for biopharmaceutical drug and biomarker development."

BioNTech is a "spin-off"-company of the Johannes Gutenberg University in Mainz, Germany.

  • Companies:
  • Fresenius-Kabi
  • BioNTech AG
See more

You may also like

Regulatory

Fresenius Kabi receives approval for tocilizumab biosimilar Tyenne

Read more
The Interleukin-6 antagonist can be used to treat various inflammatory and immune mediated conditions

Trending Articles

  1. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  4. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Fresenius Kabi receives approval for tocilizumab biosimilar Tyenne

The Interleukin-6 antagonist can be used to treat various inflammatory and immune mediated conditions
Manufacturing

AGC to support Pfizer-BioNTech Omicron vaccine

Plasmid DNA from AGC is already supplied as a starting material for the companies' COVID-19 vaccine
Ingredients

Pfizer and BioNTech announce early positive vaccine update

Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data
Finance

BioNTech completes acquisition of Neon Therapeutics

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases
Ingredients

Vifor Pharma enters Chinese joint venture with Fresenius Kabi

Joint venture will bring IV Iron to China to replace the wasteful blood transfusions that are the current prevailing treatment for iron deficiency anaemia
Design & Build

Fresenius Kabi to invest $250 million to expand Melrose Park site in Illinois, US

Building work will start next year at generic injectables plant and will be completed in 2026
Research & Development

Fresenius Medical Care establishes regenerative medicine subsidiary

Unicyte will continue successful work with University of Turin into kidney and liver diseases, diabetes and cancer
Subscribe now